Restricting valproate prescribing in women – path forward in Sri Lanka

Valproate is a well-established antiseizure medication (ASM) with efficacy across multiple seizure types. However, its teratogenic effects and risks to neurodevelopment in exposed children present significant challenges in prescribing it to women of childbearing potential (WOCP). Various countries have implemented stringent guidelines to limit valproate’s use among women. This article examines the pharmacological profile, efficacy, and reproductive health risks of sodium valproate, reviews international restriction practices, and proposes actionable steps for Sri Lanka.